Aligos Therapeutics, Inc.
ALGS
$7.34
$0.395.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.19M | 2.65M | 3.17M | 3.27M | 3.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.19M | 2.65M | 3.17M | 3.27M | 3.95M |
| Cost of Revenue | 69.45M | 68.45M | 61.28M | 68.41M | 70.27M |
| Gross Profit | -67.27M | -65.80M | -58.11M | -65.14M | -66.33M |
| SG&A Expenses | 20.72M | 20.93M | 20.40M | 21.22M | 22.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.17M | 89.38M | 81.68M | 89.62M | 93.10M |
| Operating Income | -87.99M | -86.73M | -78.50M | -86.35M | -89.15M |
| Income Before Tax | -23.88M | -86.15M | -73.84M | -52.91M | -130.88M |
| Income Tax Expenses | 314.00K | 311.00K | 346.00K | 350.00K | 331.00K |
| Earnings from Continuing Operations | -24.19 | -86.46 | -74.18 | -53.26 | -131.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.19M | -86.46M | -74.18M | -53.26M | -131.21M |
| EBIT | -87.99M | -86.73M | -78.50M | -86.35M | -89.15M |
| EBITDA | -87.06M | -85.82M | -77.56M | -85.41M | -88.13M |
| EPS Basic | -1.36 | -12.53 | -12.56 | -10.21 | -20.92 |
| Normalized Basic EPS | -0.83 | -7.81 | -7.82 | -6.35 | -13.04 |
| EPS Diluted | -8.60 | -19.76 | -19.79 | -17.45 | -20.92 |
| Normalized Diluted EPS | -0.94 | -7.92 | -7.93 | -6.46 | -13.04 |
| Average Basic Shares Outstanding | 39.51M | 35.41M | 31.31M | 27.22M | 25.06M |
| Average Diluted Shares Outstanding | 39.81M | 35.71M | 31.62M | 27.53M | 25.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |